Výsledky vyhledávání - "C J, Olbricht"

Removal of clodronate by haemodialysis in end-stage renal disease patients

Autor: A. E. Beigel, E. Rienhoff, C. J. Olbricht

Publikováno v: Nephrology Dialysis Transplantation. 10:2266-2268

Clodronate is a potent calcium-lowering drug. The effect of haemodialysis on clodronate pharmacokinetics is unknown.The removal of clodronate by haemodialysis was determined in 10 end-stage renal disease patients (ESRD). A 2-h infusion of 300 mg of c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaae7108c78e2bca2275de376304bcbc
https://doi.org/10.1093/ndt/10.12.2266

Zobrazit plný text záznamu

[Hypocomplementemic urticarial vasculitis syndrome]

Autor: R, Sessler, G, Hasche, C J, Olbricht

Publikováno v: Deutsche medizinische Wochenschrift (1946). 125(34-35)

A 40-year-old woman was admitted with recurrent membranoproliferative glomerulonephritis. For many years she had been suffering from joint pains and attacks of angio-oedema of the upper and lower lip. Physical examination was unremarkable except for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::633e7868b4dbcd19d9b0cce7e1681d1a
https://pubmed.ncbi.nlm.nih.gov/11004912

Zobrazit plný text záznamu

[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]

Autor: C J, Olbricht

Publikováno v: MMW Fortschritte der Medizin. 141(43)

Renal insufficiency and dialysis is associated with hypertriglyceridemia caused by a decreased activity of the enzyme lipoprotein lipase. Peritoneal dialysis is further complicated by hypercholesterolemia due to an increase in the synthesis of VLDL b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c9c5dc1455b1fd593065b9497924d47
https://pubmed.ncbi.nlm.nih.gov/10912119

Zobrazit plný text záznamu

Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group

Autor: C J, Olbricht, C, Wanner, J, Thiery, A, Basten

Publikováno v: Kidney international. Supplement. 71

Hyperlipidemia of the nephrotic syndrome is a risk factor for the development of systemic atherosclerosis, but it also may aggravate glomerulosclerosis and enhance the progression of glomerular disease. HMG-CoA reductase inhibitors are effective in r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a71d2ee4d331543b0fb5670801a69858
https://pubmed.ncbi.nlm.nih.gov/10412752

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání